Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · BlackRock

Blackrock Health Sciences Opportunities Portfolio Service (SHISX)

Ticker SHISX · · Holdings as of May 29, 2026

Expense ratio
1.16%$116/yr per $10k
5-yr return
+5.5%annualized
1-yr return
+15.9%as of Dec 2025
Net assets
$5.9Ball share classes
Holdings
155

Bottom line

Is SHISX a good fund? The bottom line

SHISX is the Service share class of Blackrock Health Sciences Opportunities Portfolio, an actively managed health care sector mutual fund from BlackRock.

Its expense ratio is 1.16% — about $116 a year on every $10,000 invested, more expensive than 66% of health care sector funds we track.

It returned +15.9% over one year, +5.5% a year over five years, +9.5% a year over ten (as of Dec 31, 2025, per its prospectus).

With $5.9 billion in net assets and 155 holdings, its largest position is Eli Lilly & Company (12.3%) and the top 10 make up 52% of the portfolio.

The closest lower-cost alternative we found is XLV (0.08%, 78% top-holdings overlap).

What to watch

  • Concentrated: top 10 holdings are 52% of assets
  • 12b-1 marketing fee of 0.25% a year

Updated Nov 19, 2026

What SHISX invests in

The investment objective of BlackRock Health Sciences Opportunities Portfolio (the Fund), a series of BlackRock Funds SM (the Trust), is to provide long-term growth of capital.

Under normal market conditions, the Fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. Investments in derivatives are counted toward the Funds 80% policy to the extent that they provide investment exposure to the securities included within that policy or to one or more market risk factors associated with such securities. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. Health sciences and related industries can include, but are not limited to, businesses involved in the development, production, and distribution or delivery of medical and pharmaceutical products and services, companies engaged in biotechnology and medical research and development, companies that may design…

From the fund's prospectus (filed Sep 25, 2026).

SHISX performance

Fund calendar-year total returns, 2015–2025 2015: +11.0%; 2016: −6.1%; 2017: +24.8%; 2018: +8.0%; 2019: +25.3%; 2020: +19.4%; 2021: +11.7%; 2022: −6.0%; 2023: +3.5%; 2024: +3.8%; 2025: +15.9% +11% 2015 −6% 2016 +25% 2017 +8% 2018 +25% 2019 +19% 2020 +12% 2021 −6% 2022 +4% 2023 +4% 2024 +16% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
SHISX+15.9%+5.5%+9.5%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full SHISX performance history →

What SHISX costs

On a $10,000 investment, SHISX's 1.16% expense ratio costs about $116 a year. The prospectus estimates $1,409 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full SHISX fee table →

SHISX top 10 holdings

#Holding% of fund
1Eli Lilly & Company LLY12.29%
2Johnson & Johnson JNJ8.77%
3Unitedhealth Group Inc UNH6.10%
4Merck & Company Inc MRK4.94%
5Gilead Sciences Inc GILD4.19%
6Abbvie Inc ABBV3.94%
7Amgen Inc AMGN3.37%
8Thermo Fisher Scientific Inc TMO3.02%
9Vertex Pharmaceuticals Inc VRTX2.74%
10Pfizer Inc PFE2.61%

Source: SEC Form N-PORT, period ended May 29, 2026

The top 10 make up 52% of the fund. See all top 25 holdings and asset mix →

Alternatives to SHISX

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
SPDR (State Street)XLV State Street(R) Health Care Select…0.08%78% Compare
FidelityFHLC Fidelity MSCI Health Care Index ETF0.084%78% Compare
VanguardVHT Vanguard Health Care Index Fund0.09%80% Compare
iSharesIYH iShares U.S. Healthcare ETF0.37%81% Compare
J.P. MorganJDOC JPMorgan Healthcare Leaders ETF0.65%55% Compare
SchwabSWHFX Schwab Health Care Fund0.8%67% Compare

More funds like SHISX →

SHISX FAQ

What is the expense ratio of SHISX?
SHISX's expense ratio is 1.16%, which works out to about $116 a year for every $10,000 invested. The prospectus estimates total costs of $1,409 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is SHISX a good investment?
It depends on your goals, but the data points to: concentrated: top 10 holdings are 52% of assets; 12b-1 marketing fee of 0.25% a year. This is general information, not personalized advice.
What does SHISX hold?
SHISX's largest holdings are Eli Lilly & Company (12.3%), Johnson & Johnson (8.8%), Unitedhealth Group Inc (6.1%), Merck & Company Inc (4.9%), Gilead Sciences Inc (4.2%). It holds 155 positions in total as of May 29, 2026 (SEC Form N-PORT).
What is SHISX's 5-year return?
SHISX returned +5.5% a year over the five years ending Dec 31, 2025, and +9.5% a year over ten years. Past performance does not guarantee future results.
What is a cheaper alternative to SHISX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) overlaps about 78% with SHISX and charges 0.08%.
Who manages SHISX?
SHISX is offered by BlackRock through Blackrock Funds.